The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring

Syeda Maheen Batool¹, Anudeep Yekula¹, Prerna Khanna¹, Tiffaney Hsia¹, Austin S Gamblin¹, Emil Ekanayake¹, Ana K Escobedo¹, Dong Gil You¹, Cesar M Castro¹, Hyungsoon Im¹, Tugba Kilic¹, Michelle Andrea Garlin¹, Johan Skog², Daniela M Dinulescu³, Jonathan Dudley⁴, Nishant Agrawal⁵, Jordan Cheng⁶, Fereidoun Abtin⁶, Denise R Aberle⁶, David Chia⁶, David Elashoff⁶, Tristan Grognan⁶, Kostyantyn Krysan⁶, Scott S Oh⁶, Charles Strom⁶, Michael Tu⁷, Fang Wei⁶, Rena R Xian⁴, Steven J Skates¹, David Y Zhang⁸, Thi Trinh⁹, Mark Watson¹⁰, Rebecca Aft¹⁰, Siddarth Rawal¹¹, Ashutosh Agarwal¹², Susan B Kesmodel¹², Changhuei Yang¹³, Cheng Shen¹³, Fred H Hochberg¹⁴, David T W Wong⁶, Abhijit A Patel⁹, Nickolas Papadopoulos⁴, Chetan Bettegowda⁴, Richard J Cote¹¹, Sudhir Srivastava¹⁵, Hakho Lee¹, Bob S Carter¹, Leonora Balaj¹⁶

Affiliations

¹ Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
² Exosome Diagnostics Inc., Waltham, MA, USA.
³ Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁴ Johns Hopkins University School of Medicine, Baltimore, MD, USA.
⁵ University of Chicago School of Medicine, Chicago, IL, USA.
⁶ University of California Los Angeles, Los Angeles, CA, USA.
⁷ Liquid Diagnostics LLC., Los Angeles, CA, USA.
⁸ Rice University, Houston, TX, USA.
⁹ Yale University School of Medicine, New Haven, CT, USA.
¹⁰ Washington University School of Medicine, St. Louis, MO, USA.
¹¹ Washington University School of Medicine, St. Louis, MO, USA; Circulogix Inc., St. Louis, MO, USA.
¹² University of Miami, Miami, FL, USA.
¹³ California Institute of Technology, Pasadena, CA, USA.
¹⁴ Scintillon Institute, La Jolla, CA, USA.
¹⁵ Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA.
¹⁶ Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: balaj.leonora@mgh.harvard.edu.

PMID: 37716353
PMCID: PMC10591039
DOI: 10.1016/j.xcrm.2023.101198

Review

The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring

Syeda Maheen Batool et al. Cell Rep Med. 2023.

. 2023 Oct 17;4(10):101198.

doi: 10.1016/j.xcrm.2023.101198. Epub 2023 Sep 15.

Authors

Affiliations

¹ Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
² Exosome Diagnostics Inc., Waltham, MA, USA.
³ Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁴ Johns Hopkins University School of Medicine, Baltimore, MD, USA.
⁵ University of Chicago School of Medicine, Chicago, IL, USA.
⁶ University of California Los Angeles, Los Angeles, CA, USA.
⁷ Liquid Diagnostics LLC., Los Angeles, CA, USA.
⁸ Rice University, Houston, TX, USA.
⁹ Yale University School of Medicine, New Haven, CT, USA.
¹⁰ Washington University School of Medicine, St. Louis, MO, USA.
¹¹ Washington University School of Medicine, St. Louis, MO, USA; Circulogix Inc., St. Louis, MO, USA.
¹² University of Miami, Miami, FL, USA.
¹³ California Institute of Technology, Pasadena, CA, USA.
¹⁴ Scintillon Institute, La Jolla, CA, USA.
¹⁵ Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA.
¹⁶ Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: balaj.leonora@mgh.harvard.edu.

PMID: 37716353
PMCID: PMC10591039
DOI: 10.1016/j.xcrm.2023.101198

Abstract

The emerging field of liquid biopsy stands at the forefront of novel diagnostic strategies for cancer and other diseases. Liquid biopsy allows minimally invasive molecular characterization of cancers for diagnosis, patient stratification to therapy, and longitudinal monitoring. Liquid biopsy strategies include detection and monitoring of circulating tumor cells, cell-free DNA, and extracellular vesicles. In this review, we address the current understanding and the role of existing liquid-biopsy-based modalities in cancer diagnostics and monitoring. We specifically focus on the technical and clinical challenges associated with liquid biopsy and biomarker development being addressed by the Liquid Biopsy Consortium, established through the National Cancer Institute. The Liquid Biopsy Consortium has developed new methods/assays and validated existing methods/technologies to capture and characterize tumor-derived circulating cargo, as well as addressed existing challenges and provided recommendations for advancing biomarker assays.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare no competing interests.

Figures

**Figure 1**
Overview of the Liquid Biopsy Consortium and the different technologies investigated (A) A summary of the academic-industrial partnership collaborations is provided, highlighting the leading principal investigators, target analytes, various liquid biopsy technologies used, and cancers of interest.

See this image and copyright information in PMC

References

1. Website U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, Based on 2019 Submission Data (1999-2017): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; www.cdc.gov/cancer/dataviz, released in June 2020.
1. Byers T., Wender R.C., Jemal A., Baskies A.M., Ward E.E., Brawley O.W. The American Cancer Society challenge goal to reduce US cancer mortality by 50% between 1990 and 2015: Results and reflections. CA A Cancer J. Clin. 2016;66:359–369. - PubMed
1. Domínguez-Vigil I.G., Moreno-Martínez A.K., Wang J.Y., Roehrl M.H.A., Barrera-Saldaña H.A. The dawn of the liquid biopsy in the fight against cancer. Oncotarget. 2018;9:2912–2922. - PMC - PubMed
1. Zhu X., Weiser E., Jacobson D.J., Griffin J.M., Limburg P.J., Finney Rutten L.J. Provider-perceived barriers to patient adherence to colorectal cancer screening. Prev. Med. Rep. 2022;25:101681. - PMC - PubMed
1. ACS Breast Cancer Early Detection Recommendations https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-de....

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring

Affiliations

The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources